Cellectis (FRA:ZVAA) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


FRA:ZVAA Cellectis SA FRA:ZVAA
64 GF Score
Price €2.44
GF Value €3.05
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cellectis Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cellectis's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:ZVAA vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Cellectis's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cellectis's Margin of Safety % (DCF Earnings Based) falls into.


FRA:ZVAA
64GF Score
Cellectis SA FRA:ZVAA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cellectis (FRA:ZVAA) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of €2.44 is trading 20% below its estimated GF Value™ of €3.05. GuruFocus considers Cellectis to be Modestly Undervalued.

Key valuation signals for FRA:ZVAA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €3.05 vs. price of €2.44 (20% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the FRA:ZVAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
64GF Score

Get the complete analysis for FRA:ZVAA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price
€3.05
GF Value